Pharmaceuticals News and Research

RSS

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.

7 Nov 2014

Applying lessons learnt from failed Alzheimer's studies for future research

Disappointing results in clinical Alzheimer's studies discourage doctors and scientists from continuing their research into ɣ-secretases and a possible treatment against Alzheimer's disease. In the prestigious journal Cell, the Alzheimer's expert Bart De Strooper (VIB-KU Leuven) argues that these studies are not pointless, but merely indicate what the next steps should be for the Alzheimer's research.

7 Nov 2014

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

The Multiple Myeloma Research Foundation today announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM).

6 Nov 2014

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.

6 Nov 2014

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino's expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing.

6 Nov 2014

Quadrupole time-of-flight mass spectrometry for life science research analysis announced by Bruker

Bruker Corporation (NASDAQ: BRKR) announced today, the evolution of their maXis™ line of ultrahigh-resolution quadrupole time-of-flight (UHR-qTOF) mass spectrometers, bringing industry-leading resolution and mass accuracy to the liquid chromatography, time-of-flight MS market space.

From Bruker 6 Nov 2014

Study looks at new diagnostic, treatment approaches to neurological conditions

Despite great advances in understanding how the human brain works, psychiatric conditions, neurodegenerative disorders, and brain injuries are on the rise. Progress in the development of new diagnostic and treatment approaches appears to have stalled. In a special issue of the Cell Press journal Neuron, experts look at the challenges associated with "translational neuroscience," or efforts to bring advances in the lab to the patients who need them.

6 Nov 2014

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1.

5 Nov 2014

Light-activated diabetes drug: an interview with Dr David Hodson

We've known about chemicals that can be light-activated for about five to ten years now. They’ve mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.

5 Nov 2014

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus, as reported this week in the online edition of the journal Molecular Pharmaceutics.

5 Nov 2014

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.

5 Nov 2014

Glenmark gets final approval from FDA for Omeprazole DR Capsules ANDA

Glenmark Generics Inc. USA, the subsidiary of Glenmark Generics Limited, has been granted final approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration for Omeprazole Delayed Release Capsules, their generic version of Prilosec by AstraZeneca.

5 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

Myriad Genetics, Inc. announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc., a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie’s novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

4 Nov 2014

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Dana-Farber Cancer Institute (Dana-Farber) and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

4 Nov 2014

Researchers identify potential therapeutic target for glioblastoma

A multicenter team of researchers has identified an enzyme key to the survival and spread of glioblastoma cancer cells that is not present in healthy brain cells, making the enzyme a promising therapeutic target.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014

Pharmaceuticals News and Research

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Applying lessons learnt from failed Alzheimer's studies for future research

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Acino recognized with 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership

Quadrupole time-of-flight mass spectrometry for life science research analysis announced by Bruker

Study looks at new diagnostic, treatment approaches to neurological conditions

Hospira launches Paricalcitol Injection

Light-activated diabetes drug: an interview with Dr David Hodson

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

Glenmark gets final approval from FDA for Omeprazole DR Capsules ANDA

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

AbbVie and Myriad Genetics expand Tumor BRACAnalysis CDx collaboration

Astellas, Dana-Farber to develop K-Ras inhibitors for treatment of lung, pancreatic cancers

Researchers identify potential therapeutic target for glioblastoma

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Nasal vaccine shows promise against Ebola virus

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence